The Fund seeks to achieve long-term capital appreciation by investing primarily in equity securities of companies in any country outside of Canada and the United States.
Is this fund right for you?
- You want your money to grow over a longer term.
- You want to invest in companies outside of Canada and the U.S.
- You're comfortable with a medium level of risk.
Risk Rating
How is the fund invested?
(as of February 28, 2025)
Asset allocation (%)
|
Name |
Percent |
|
International Equity |
94.8 |
|
US Equity |
4.1 |
|
Cash and Equivalents |
1.1 |
Geographic allocation (%)
|
Name |
Percent |
|
France |
16.6 |
|
United Kingdom |
15.2 |
|
Japan |
14.6 |
|
Germany |
13.9 |
|
Sweden |
8.2 |
|
India |
5.2 |
|
Taiwan |
4.6 |
|
Denmark |
4.5 |
|
United States |
4.1 |
|
Other |
13.1 |
Sector allocation (%)
|
Name |
Percent |
|
Industrial Goods |
19.0 |
|
Consumer Goods |
15.4 |
|
Financial Services |
14.6 |
|
Technology |
13.7 |
|
Healthcare |
12.1 |
|
Real Estate |
5.4 |
|
Basic Materials |
5.1 |
|
Industrial Services |
3.6 |
|
Consumer Services |
3.5 |
|
Other |
7.6 |
Growth of $10,000
(since inception)
Data not available based on date of inception
Fund details
(as of February 28, 2025)
Top holdings |
% |
Sap SE |
6.4 |
HDFC Bank Ltd - ADR |
5.2 |
L'Air Liquide SA |
5.1 |
Taiwan Semiconductor Manufactrg Co Ltd - ADR |
4.6 |
Novo Nordisk A/S Cl B |
4.5 |
Ferguson Enterprises Inc |
4.1 |
Sony Group Corp |
4.1 |
AstraZeneca PLC |
4.0 |
Siemens AG Cl N |
3.8 |
Deutsche Boerse AG Cl N |
3.7 |
Total allocation in top holdings |
45.5 |
Portfolio characteristics |
|
Standard deviation |
13.9% |
Dividend yield |
1.8% |
Average market cap (million) |
$263,821.3 |
Understanding returns
Annual compound returns (%)
1 MO |
3 MO |
YTD |
1 YR |
{{snapShot.Return1Mth|customNumber:1}} | {{snapShot.Return3Mth|customNumber:1}} | {{snapShot.ReturnYTD|customNumber:1}} | {{snapShot.Return1Yr|customNumber:1}} |
3 YR |
5 YR |
10 YR |
INCEPTION |
{{snapShot.Return3Yr|customNumber:1}} | {{snapShot.Return5Yr|customNumber:1}} | {{snapShot.Return10Yr|customNumber:1}} | {{snapShot.ReturnInception|customNumber:1}} |
Calendar year returns (%)
2024 |
2023 |
2022 |
2021 |
{{snapShot.Return1YrCalendar|customNumber:1}} | {{snapShot.Return2YrCalendar|customNumber:1}} | {{snapShot.Return3YrCalendar|customNumber:1}} | {{snapShot.Return4YrCalendar|customNumber:1}} |
2020 |
2019 |
2018 |
2017 |
{{snapShot.Return5YrCalendar|customNumber:1}} | {{snapShot.Return6YrCalendar|customNumber:1}} | {{snapShot.Return7YrCalendar|customNumber:1}} | {{snapShot.Return8YrCalendar|customNumber:1}} |
Range of returns over five years
(July 1, 2019 - April 30, 2025)
Best return |
Best period end date |
Worst return |
Worst period end date |
8.6% |
Sept. 2024 |
5.9% |
Dec. 2024 |
Average return |
% of periods with positive returns |
Number of positive periods |
Number of negative periods |
7.5% |
100.0% |
11 |
0 |
Q1 2025 Fund Commentary
Market commentary
Global equities declined in March, in part because of geopolitical unrest and uncertainty. Europe saw a notable development as Germany’s government approved reforms to its constitutional debt brake, a major shift in fiscal policy. Investor optimism rose as the shift could unlock a wave of investments focused on defence, energy security and infrastructure.
Performance
The Fund’s relative exposure to Deutsche Boerse AG had the most positive impact on performance, after the company benefited from its positive fourth-quarter earnings announcement. Relative exposure to Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC) and Novo Nordisk AS was negative for performance. Novo Nordisk was negatively affected by disappointing clinical trial results for CagriSema and lower-than-expected demand for its obesity drugs. TSMC’s share price fell because of weakness in information technology stocks and uncertainty about U.S. tariffs.
At the sector level, stock selection in consumer discretionary and materials had the most positive impact on the Fund’s performance. Security selection in health care and industrials had a negative impact on performance.
At a regional level, underweight exposure to Japan had a positive impact on performance. Overweight exposure to Denmark and exposures to Taiwan and Indonesia had a negative effect on performance.
Portfolio activity
There was no significant activity in the Fund during the quarter.
Outlook
The Fund’s holdings are a balanced structure of companies in different parts of the growth spectrum. The sub-advisor is focused on growth companies with good cash flows and strong balance sheets. The sub-advisor believes that these elements are important for long-term investing and in the current uncertain market environment.